- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02529189
Investigating the Effects of Dietary Nitrate on Vascular Function, Platelet Reactivity and Restenosis in Stable Angina (NITRATE-OCT)
A Randomised, Double-blind, Placebo-controlled Study Investigating the Effects of Dietary Nitrate on Vascular Function, Platelet Reactivity and Restenosis in Stable Angina
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
To address the aims a proof-of-concept study will be conducted to ascertain whether a dietary nitrate approach might prove useful adjunctive therapy improving vascular function in patients with stable angina post elective angioplasty.
Design: A prospective randomised, single-centre, double-blind, placebo-controlled trial
Setting: Patients with stable angina and single/multiple coronary artery stenosis undergoing elective percutaneous coronary intervention (PCI) who are haemodynamically stable (systolic BP>100 mmHg). These patients will be recruited at The Barts Health Heart Centre, based at St. Bartholomew's Hospital. This is one of the biggest centres in the United Kingdom, serving a population of almost two million people from The City of London and The North East up to the M25 and is a 24/7 centre performing approximately 2000 non-primary angioplasties a year.
The study will take place in the Clinical Trials Unit, William Harvey Heart Centre.
Target population: A total of 300 patients (male and female, age 18-85) with stable angina as per requirements indicated above. Follow-up will take place in the Clinical Trials Unit, William Harvey Research Institute.
Treatment: Patients will be randomised (using an on line randomisation database) to receive 70 ml of a beetroot juice concentrate containing 4-5 mmol nitrate or nitrate-deplete placebo juice concentrate. This intervention will be taken by the patient daily from one day prior to re-establishment of flow with PCI and stent implantation.
Analysis: We will analyse the results based on an intention to treat analysis. We will also carry out further per protocol analyses and a subgroup analysis on patients who are on organic nitrates as part of their routine therapy and a comparison of DES (drug-eluting stents) versus BMS (bare-metal stents).
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, EC1M 6BQ
- William Harvey Research Institute, Barts and The London School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with stable angina diagnosed by a cardiologist on optimal medical therapy undergoing angioplasty to treat residual symptoms.
- Aged 18-85
- Patients able and willing to give their written informed consent.
- Patients undergoing successful PCI procedure.
Exclusion Criteria:
- Unstable ischaemic heart disease, with an episode of chest pain in less than 24 hours.
- Patients who have had previous coronary artery bypass surgery (CABG), if they are undergoing angioplasty within a non-native vessel.
- Patients undergoing angioplasty with a bio-absorbable stent.
- Current diagnosis of or treatment for malignancy, other than non-melanoma skin cancer.
- Current life-threatening condition other than vascular disease that may prevent a subject completing the study.
- Use of an investigational device or investigational drug within 30 days or 5 half-lives (whichever is the longer) preceding the first dose of study medication.
- Patients considered unsuitable to participate by the research team (e.g., due to medical reasons, laboratory abnormalities, or subject's unwillingness to comply with all study related procedures).
- Severe acute infection, or significant trauma (burns, fractures).
- Pregnancy. This will be tested by urine human chorionic gonadotropin (hCG) measurement
- History of alcohol or drug abuse within the past 6 months.
- A history of heart failure New York Heart Association (NYHA) class 3-4 or severe left ventricular dysfunction (left ventricular ejection fraction of <30%) regardless of symptom status.
- Systemic autoimmune disease such as rheumatoid arthritis, connective tissue disease, or other conditions known to be associated with chronic inflammation such as inflammatory bowel disease.
- Patients who have donated > 500mls blood within 56 days prior to study medication administration.
- Anaemia with Hb <10g/dl, or any other known blood disorder or significant illness that may affect platelet function, and coagulation.
- A history of chronic viral hepatitis (including presence of hepatitis B surface antigen or hepatitis C antibody or other chronic hepatic disorder) or HIV.
- Abnormal liver function due to acute or chronic liver conditions 3 x upper limit of normal at screening.
- Renal impairment with creatinine clearance (eGFR) of 35ml/min at screening.
- If patients are on mouthwash, they must be willing to stop using this at least 1 week before the start of the study and throughout the duration that they are involved in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Nitrate-rich beetroot juice
70 ml of a beetroot juice concentrate containing ~5 mmol nitrate
|
70 ml of beetroot juice containing ~5 mmol of inorganic nitrate
70 ml of beetroot juice which is nitrate-depleted
|
Placebo Comparator: Nitrate-deplete beetroot juice
70 ml of a beetroot juice concentrate that is nitrate-depleted
|
70 ml of beetroot juice containing ~5 mmol of inorganic nitrate
70 ml of beetroot juice which is nitrate-depleted
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Difference between groups in In-stent late loss, where late loss is defined as the difference between the minimum luminal diameter (MLD).
Time Frame: 6 months +/- 1 month post intervention
|
6 months +/- 1 month post intervention
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Difference from baseline within the group and between groups in endothelial function assessed by flow-mediated dilatation of the brachial artery at 6 months compared to pre-procedure assessment.
Time Frame: 6 months and 12 months post intervention
|
6 months and 12 months post intervention
|
Difference from baseline within the group and between groups in target vessel revascularisation (TVR).
Time Frame: 6 months post intervention
|
6 months post intervention
|
Difference from baseline within the group and between groups in restenosis rate (diameter >50%).
Time Frame: 6 months post intervention
|
6 months post intervention
|
Difference from baseline within the group and between groups in in-segment late loss.
Time Frame: 6 months post intervention
|
6 months post intervention
|
Difference from baseline between groups in major adverse cardiac events (i.e. Myocardial Infarction, death, Cerebrovascular Accident, Target Vascular Revascularisation).
Time Frame: 6 months, 12 months and 24 months post intervention
|
6 months, 12 months and 24 months post intervention
|
Difference from baseline within the group and between groups in inflammatory markers.
Time Frame: 6 months and 12 months post intervention
|
6 months and 12 months post intervention
|
Difference from baseline within the group and between groups in plasma and erythrocyte nitrite reductase.
Time Frame: 6 months and 12 months post intervention
|
6 months and 12 months post intervention
|
Difference from baseline within the group and between groups in changes in plasma xanthine oxidase activity.
Time Frame: 6 months and 12 months post intervention
|
6 months and 12 months post intervention
|
Difference from baseline within the group and between groups high-sensitivity C-reactive protein (hsCRP).
Time Frame: 6 months and 12 months post intervention
|
6 months and 12 months post intervention
|
Difference from baseline within the group and between groups in Interleukin-6 (IL-6).
Time Frame: 6 months and 12 months post intervention
|
6 months and 12 months post intervention
|
Difference from baseline within the group and between groups in platelet activation (P-Selectin and platelet-monocyte aggregates).
Time Frame: 6 months and 12 months post intervention
|
6 months and 12 months post intervention
|
Difference from baseline within the group and between groups in platelet aggregation ex vivo (ADP, collagen, arachidonic acid).
Time Frame: 6 months and 12 months post intervention
|
6 months and 12 months post intervention
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Amrita Ahluwalia, PhD, Queen Mary University of London
Publications and helpful links
General Publications
- Kapil V, Khambata RS, Robertson A, Caulfield MJ, Ahluwalia A. Dietary nitrate provides sustained blood pressure lowering in hypertensive patients: a randomized, phase 2, double-blind, placebo-controlled study. Hypertension. 2015 Feb;65(2):320-7. doi: 10.1161/HYPERTENSIONAHA.114.04675. Epub 2014 Nov 24.
- Ghosh SM, Kapil V, Fuentes-Calvo I, Bubb KJ, Pearl V, Milsom AB, Khambata R, Maleki-Toyserkani S, Yousuf M, Benjamin N, Webb AJ, Caulfield MJ, Hobbs AJ, Ahluwalia A. Enhanced vasodilator activity of nitrite in hypertension: critical role for erythrocytic xanthine oxidoreductase and translational potential. Hypertension. 2013 May;61(5):1091-102. doi: 10.1161/HYPERTENSIONAHA.111.00933. Epub 2013 Apr 15.
- Rathod KS, Jones DA, Van-Eijl TJ, Tsang H, Warren H, Hamshere SM, Kapil V, Jain AK, Deaner A, Poulter N, Caulfield MJ, Mathur A, Ahluwalia A. Randomised, double-blind, placebo-controlled study investigating the effects of inorganic nitrate on vascular function, platelet reactivity and restenosis in stable angina: protocol of the NITRATE-OCT study. BMJ Open. 2016 Dec 20;6(12):e012728. doi: 10.1136/bmjopen-2016-012728.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15/LO/0555
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Diseases
-
Medical College of WisconsinRecruitingCardiovascular Diseases | Cardiovascular Risk Factor | Cardiovascular HealthUnited States
-
Hospital Mutua de TerrassaCompleted
-
Oregon Health and Science UniversityCompletedCardiovascular Disease | Cardiovascular Risk FactorsUnited States
-
Women's College HospitalUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Brigham... and other collaboratorsUnknownCARDIOVASCULAR DISEASESCanada, United States
-
Groupe Hospitalier Paris Saint JosephTerminatedCARDIOVASCULAR DISEASESFrance
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
Nanjing Medical UniversityRecruiting
-
Centre Hospitalier Universitaire de la RéunionRecruitingCardiovascular DiseaseFrance
-
National Heart, Lung, and Blood Institute (NHLBI)RecruitingCardiovascular DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)RecruitingCardiovascular DiseaseUnited States
Clinical Trials on Beetroot Juice
-
Universidad Francisco de VitoriaUniversity of Alcala; University of SevilleCompleted
-
Bangor UniversityCompleted
-
University Hospital, GhentUniversity GhentTerminated
-
University of ManchesterCompleted
-
Queen Mary University of LondonCompleted
-
Wake Forest University Health SciencesCompletedStroke | Ischemic Stroke | Cerebrovascular AccidentUnited States
-
University of Colorado, BoulderRecruitingChronic Kidney DiseaseUnited States
-
Penn State UniversityActive, not recruitingMetabolic SyndromeUnited States
-
University of ReadingSaudi Cultural BureauCompletedNo Dental Disease | Non-smokingUnited Kingdom
-
Bournemouth UniversityInstitute of Bioengineering and Bioimaging (IBB); University of Portsmouth; Loughborough...Completed